Prescribing MiSight 1 day for Myopia Management and new clinical trial data

Prescribing MiSight 1 day for Myopia Management and new clinical trial data

Summary

To quote Professor Ian Flitcroft, “there is no safe level of myopia”. This presentation, hosted by CooperVision, will highlight the risks of myopia and the need for early intervention. The prescribing of MiSight 1 day contact lenses in myopia management will be discussed, in particular, key messages that need to be conveyed to parents of myopic children. New 5-year results from an ongoing multi-year international clinical trial will be shared.

Learning Objectives

  • 42 Participants should be able to understand that there is no safe level of myopia and that strategies to minimise onset and progression are vital.
  • 43 Participants should be able to understand the lifetime risks of visual impairment and how these risks increase with axial length.
  • 44 Participants should be able to understand the principles of dual-focus optics and the efficacy of the MiSight 1 day contact lens for myopia management.
  • Participants should be able to understand the efficacy of low dose atropine in myopia control in comparison to other treatments